#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0475] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences.
1-1	0-1	[	_	_	
1-2	1-5	0475	_	_	
1-3	5-6	]	_	_	
1-4	7-15	Antibody	_	_	
1-5	16-24	variable	_	_	
1-6	25-32	domains	_	_	
1-7	33-37	with	_	_	
1-8	38-41	the	_	_	
1-9	42-49	desired	_	_	
1-10	50-57	binding	_	_	
1-11	58-71	specificities	_	_	
1-12	72-73	(	_	_	
1-13	73-89	antibody-antigen	_	_	
1-14	90-99	combining	_	_	
1-15	100-105	sites	_	_	
1-16	105-106	)	_	_	
1-17	107-110	can	_	_	
1-18	111-113	be	_	_	
1-19	114-119	fused	_	_	
1-20	120-122	to	_	_	
1-21	123-137	immunoglobulin	_	_	
1-22	138-146	constant	_	_	
1-23	147-153	domain	_	_	
1-24	154-163	sequences	_	_	
1-25	163-164	.	_	_	

#Text=For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121: 210 (1986).
#Text=[0476] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
2-1	165-168	For	_	_	
2-2	169-176	further	_	_	
2-3	177-184	details	_	_	
2-4	185-187	of	_	_	
2-5	188-198	generating	_	_	
2-6	199-209	bispecific	_	_	
2-7	210-220	antibodies	_	_	
2-8	221-224	see	_	_	
2-9	224-225	,	_	_	
2-10	226-229	for	_	_	
2-11	230-237	example	_	_	
2-12	237-238	,	_	_	
2-13	239-245	Suresh	_	_	
2-14	246-248	et	_	_	
2-15	249-251	al	_	_	
2-16	251-252	.	_	_	
2-17	252-253	,	_	_	
2-18	254-261	Methods	_	_	
2-19	262-264	in	_	_	
2-20	265-275	Enzymology	_	_	
2-21	275-276	,	_	_	
2-22	277-280	121	_	_	
2-23	280-281	:	_	_	
2-24	282-285	210	_	_	
2-25	286-287	(	_	_	
2-26	287-291	1986	_	_	
2-27	291-292	)	_	_	
2-28	292-293	.	_	_	
2-29	294-295	[	*[1]	3-23[2_1]	
2-30	295-299	0476	*[1]	_	
2-31	299-300	]	*[1]	_	
2-32	301-310	According	*[1]	_	
2-33	311-313	to	*[1]	_	
2-34	314-321	another	*[1]	_	
2-35	322-330	approach	*[1]	_	
2-36	331-340	described	*[1]	_	
2-37	341-343	in	*[1]	_	
2-38	344-346	WO	*[1]	_	
2-39	347-349	96	*[1]	_	
2-40	349-350	/	*[1]	_	
2-41	350-355	27011	*[1]	_	
2-42	355-356	,	*[1]	_	
2-43	357-360	the	*[1]	_	
2-44	361-370	interface	*[1]	_	
2-45	371-378	between	*[1]	_	
2-46	379-380	a	*[1]	_	
2-47	381-385	pair	*[1]	_	
2-48	386-388	of	*[1]	_	
2-49	389-397	antibody	*[1]	_	
2-50	398-407	molecules	*[1]	_	
2-51	408-411	can	*[1]	_	
2-52	412-414	be	*[1]	_	
2-53	415-425	engineered	*[1]	_	
2-54	426-428	to	*[1]	_	
2-55	429-437	maximize	*[1]	_	
2-56	438-441	the	*[1]	_	
2-57	442-452	percentage	*[1]	_	
2-58	453-455	of	*[1]	_	
2-59	456-468	heterodimers	*[1]	_	
2-60	469-474	which	*[1]	_	
2-61	475-478	are	*[1]	_	
2-62	479-488	recovered	*[1]	_	
2-63	489-493	from	*[1]	_	
2-64	494-505	recombinant	*[1]	_	
2-65	506-510	cell	*[1]	_	
2-66	511-518	culture	*[1]	_	
2-67	518-519	.	*[1]	_	

#Text=The preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
#Text=[0477] In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replace with larger side chains (e. g., tyrosine or tryptophan).
#Text=[0478] Compensatory "cavities" of identical or similar size to the large side chain (s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e. g., alanine or threonine).
3-1	520-523	The	_	_	
3-2	524-533	preferred	_	_	
3-3	534-543	interface	_	_	
3-4	544-553	comprises	_	_	
3-5	554-556	at	_	_	
3-6	557-562	least	_	_	
3-7	563-564	a	_	_	
3-8	565-569	part	_	_	
3-9	570-572	of	_	_	
3-10	573-576	the	_	_	
3-11	577-580	CH3	_	_	
3-12	581-587	region	_	_	
3-13	588-590	of	_	_	
3-14	591-593	an	_	_	
3-15	594-602	antibody	_	_	
3-16	603-611	constant	_	_	
3-17	612-618	domain	_	_	
3-18	618-619	.	_	_	
3-19	620-621	[	_	_	
3-20	621-625	0477	_	_	
3-21	625-626	]	_	_	
3-22	627-629	In	_	_	
3-23	630-634	this	*[2]	_	
3-24	635-641	method	*[2]	_	
3-25	641-642	,	_	_	
3-26	643-646	one	_	_	
3-27	647-649	or	_	_	
3-28	650-654	more	_	_	
3-29	655-660	small	_	_	
3-30	661-666	amino	_	_	
3-31	667-671	acid	_	_	
3-32	672-676	side	_	_	
3-33	677-683	chains	_	_	
3-34	684-688	from	_	_	
3-35	689-692	the	_	_	
3-36	693-702	interface	_	_	
3-37	703-705	of	_	_	
3-38	706-709	the	_	_	
3-39	710-715	first	_	_	
3-40	716-724	antibody	_	_	
3-41	725-733	molecule	_	_	
3-42	734-737	are	_	_	
3-43	738-745	replace	_	_	
3-44	746-750	with	_	_	
3-45	751-757	larger	_	_	
3-46	758-762	side	_	_	
3-47	763-769	chains	_	_	
3-48	770-771	(	_	_	
3-49	771-772	e	_	_	
3-50	772-773	.	_	_	
3-51	774-775	g	_	_	
3-52	775-776	.	_	_	
3-53	776-777	,	_	_	
3-54	778-786	tyrosine	_	_	
3-55	787-789	or	_	_	
3-56	790-800	tryptophan	_	_	
3-57	800-801	)	_	_	
3-58	801-802	.	_	_	
3-59	803-804	[	_	_	
3-60	804-808	0478	_	_	
3-61	808-809	]	_	_	
3-62	810-822	Compensatory	_	_	
3-63	823-824	"	_	_	
3-64	824-832	cavities	_	_	
3-65	832-833	"	_	_	
3-66	834-836	of	_	_	
3-67	837-846	identical	_	_	
3-68	847-849	or	_	_	
3-69	850-857	similar	_	_	
3-70	858-862	size	_	_	
3-71	863-865	to	_	_	
3-72	866-869	the	_	_	
3-73	870-875	large	_	_	
3-74	876-880	side	_	_	
3-75	881-886	chain	_	_	
3-76	887-888	(	_	_	
3-77	888-889	s	_	_	
3-78	889-890	)	_	_	
3-79	891-894	are	_	_	
3-80	895-902	created	_	_	
3-81	903-905	on	_	_	
3-82	906-909	the	_	_	
3-83	910-919	interface	_	_	
3-84	920-922	of	_	_	
3-85	923-926	the	_	_	
3-86	927-933	second	_	_	
3-87	934-942	antibody	_	_	
3-88	943-951	molecule	_	_	
3-89	952-954	by	_	_	
3-90	955-964	replacing	_	_	
3-91	965-970	large	_	_	
3-92	971-976	amino	_	_	
3-93	977-981	acid	_	_	
3-94	982-986	side	_	_	
3-95	987-993	chains	_	_	
3-96	994-998	with	_	_	
3-97	999-1006	smaller	_	_	
3-98	1007-1011	ones	_	_	
3-99	1012-1013	(	_	_	
3-100	1013-1014	e	_	_	
3-101	1014-1015	.	_	_	
3-102	1016-1017	g	_	_	
3-103	1017-1018	.	_	_	
3-104	1018-1019	,	_	_	
3-105	1020-1027	alanine	_	_	
3-106	1028-1030	or	_	_	
3-107	1031-1040	threonine	_	_	
3-108	1040-1041	)	_	_	
3-109	1041-1042	.	_	_	

#Text=This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
#Text=[0479] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e. g., F (ab')2 bispecific antibodies).
4-1	1043-1047	This	_	_	
4-2	1048-1056	provides	_	_	
4-3	1057-1058	a	_	_	
4-4	1059-1068	mechanism	_	_	
4-5	1069-1072	for	_	_	
4-6	1073-1083	increasing	_	_	
4-7	1084-1087	the	_	_	
4-8	1088-1093	yield	_	_	
4-9	1094-1096	of	_	_	
4-10	1097-1100	the	_	_	
4-11	1101-1112	heterodimer	_	_	
4-12	1113-1117	over	_	_	
4-13	1118-1123	other	_	_	
4-14	1124-1132	unwanted	_	_	
4-15	1133-1145	end-products	_	_	
4-16	1146-1150	such	_	_	
4-17	1151-1153	as	_	_	
4-18	1154-1164	homodimers	_	_	
4-19	1164-1165	.	_	_	
4-20	1166-1167	[	_	_	
4-21	1167-1171	0479	_	_	
4-22	1171-1172	]	_	_	
4-23	1173-1183	Bispecific	_	_	
4-24	1184-1194	antibodies	_	_	
4-25	1195-1198	can	_	_	
4-26	1199-1201	be	_	_	
4-27	1202-1210	prepared	_	_	
4-28	1211-1213	as	_	_	
4-29	1214-1218	full	_	_	
4-30	1219-1225	length	_	_	
4-31	1226-1236	antibodies	_	_	
4-32	1237-1239	or	_	_	
4-33	1240-1248	antibody	_	_	
4-34	1249-1258	fragments	_	_	
4-35	1259-1260	(	_	_	
4-36	1260-1261	e	_	_	
4-37	1261-1262	.	_	_	
4-38	1263-1264	g	_	_	
4-39	1264-1265	.	_	_	
4-40	1265-1266	,	_	_	
4-41	1267-1268	F	_	_	
4-42	1269-1270	(	_	_	
4-43	1270-1272	ab	_	_	
4-44	1272-1273	'	_	_	
4-45	1273-1274	)	_	_	
4-46	1274-1275	2	_	_	
4-47	1276-1286	bispecific	_	_	
4-48	1287-1297	antibodies	_	_	
4-49	1297-1298	)	_	_	
4-50	1298-1299	.	_	_	

#Text=Techniques for generating bispecific antibodies from antibody fragments have been described in the literature.
5-1	1300-1310	Techniques	_	_	
5-2	1311-1314	for	_	_	
5-3	1315-1325	generating	_	_	
5-4	1326-1336	bispecific	_	_	
5-5	1337-1347	antibodies	_	_	
5-6	1348-1352	from	_	_	
5-7	1353-1361	antibody	_	_	
5-8	1362-1371	fragments	_	_	
5-9	1372-1376	have	_	_	
5-10	1377-1381	been	_	_	
5-11	1382-1391	described	_	_	
5-12	1392-1394	in	_	_	
5-13	1395-1398	the	_	_	
5-14	1399-1409	literature	_	_	
5-15	1409-1410	.	_	_	

#Text=For example, bispecific antibodies can be prepared using chemical linkage.
6-1	1411-1414	For	_	_	
6-2	1415-1422	example	_	_	
6-3	1422-1423	,	_	_	
6-4	1424-1434	bispecific	_	_	
6-5	1435-1445	antibodies	_	_	
6-6	1446-1449	can	_	_	
6-7	1450-1452	be	_	_	
6-8	1453-1461	prepared	_	_	
6-9	1462-1467	using	_	_	
6-10	1468-1476	chemical	_	_	
6-11	1477-1484	linkage	_	_	
6-12	1484-1485	.	_	_	

#Text=Brennan et al., Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F (ab')2 fragments.
7-1	1486-1493	Brennan	_	_	
7-2	1494-1496	et	_	_	
7-3	1497-1499	al	_	_	
7-4	1499-1500	.	_	_	
7-5	1500-1501	,	_	_	
7-6	1502-1509	Science	_	_	
7-7	1509-1510	,	_	_	
7-8	1511-1514	229	_	_	
7-9	1514-1515	:	_	_	
7-10	1516-1518	81	_	_	
7-11	1519-1520	(	_	_	
7-12	1520-1524	1985	_	_	
7-13	1524-1525	)	_	_	
7-14	1526-1534	describe	_	_	
7-15	1535-1536	a	_	_	
7-16	1537-1546	procedure	_	_	
7-17	1547-1554	wherein	_	_	
7-18	1555-1561	intact	_	_	
7-19	1562-1572	antibodies	_	_	
7-20	1573-1576	are	_	_	
7-21	1577-1592	proteolytically	_	_	
7-22	1593-1600	cleaved	_	_	
7-23	1601-1603	to	_	_	
7-24	1604-1612	generate	_	_	
7-25	1613-1614	F	_	_	
7-26	1615-1616	(	_	_	
7-27	1616-1618	ab	_	_	
7-28	1618-1619	'	_	_	
7-29	1619-1620	)	_	_	
7-30	1620-1621	2	_	_	
7-31	1622-1631	fragments	_	_	
7-32	1631-1632	.	_	_	

#Text=These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.
8-1	1633-1638	These	_	_	
8-2	1639-1648	fragments	_	_	
8-3	1649-1652	are	_	_	
8-4	1653-1660	reduced	_	_	
8-5	1661-1663	in	_	_	
8-6	1664-1667	the	_	_	
8-7	1668-1676	presence	_	_	
8-8	1677-1679	of	_	_	
8-9	1680-1683	the	_	_	
8-10	1684-1691	dithiol	_	_	
8-11	1692-1702	complexing	_	_	
8-12	1703-1708	agent	_	_	
8-13	1709-1715	sodium	_	_	
8-14	1716-1724	arsenite	_	_	
8-15	1725-1727	to	_	_	
8-16	1728-1737	stabilize	_	_	
8-17	1738-1745	vicinal	_	_	
8-18	1746-1754	dithiols	_	_	
8-19	1755-1758	and	_	_	
8-20	1759-1766	prevent	_	_	
8-21	1767-1781	intermolecular	_	_	
8-22	1782-1791	disulfide	_	_	
8-23	1792-1801	formation	_	_	
8-24	1801-1802	.	_	_	

#Text=The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
9-1	1803-1806	The	_	_	
9-2	1807-1810	Fab	_	_	
9-3	1810-1811	'	_	_	
9-4	1812-1821	fragments	_	_	
9-5	1822-1831	generated	_	_	
9-6	1832-1835	are	_	_	
9-7	1836-1840	then	_	_	
9-8	1841-1850	converted	_	_	
9-9	1851-1853	to	_	_	
9-10	1854-1871	thionitrobenzoate	_	_	
9-11	1872-1873	(	_	_	
9-12	1873-1876	TNB	_	_	
9-13	1876-1877	)	_	_	
9-14	1878-1889	derivatives	_	_	
9-15	1889-1890	.	_	_	

#Text=One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
10-1	1891-1894	One	_	_	
10-2	1895-1897	of	_	_	
10-3	1898-1901	the	_	_	
10-4	1902-1905	Fab	_	_	
10-5	1905-1906	'	_	_	
10-6	1906-1907	-	_	_	
10-7	1907-1910	TNB	_	_	
10-8	1911-1922	derivatives	_	_	
10-9	1923-1925	is	_	_	
10-10	1926-1930	then	_	_	
10-11	1931-1942	reconverted	_	_	
10-12	1943-1945	to	_	_	
10-13	1946-1949	the	_	_	
10-14	1950-1953	Fab	_	_	
10-15	1953-1954	'	_	_	
10-16	1954-1955	-	_	_	
10-17	1955-1960	thiol	_	_	
10-18	1961-1963	by	_	_	
10-19	1964-1973	reduction	_	_	
10-20	1974-1978	with	_	_	
10-21	1979-1997	mercaptoethylamine	_	_	
10-22	1998-2001	and	_	_	
10-23	2002-2004	is	_	_	
10-24	2005-2010	mixed	_	_	
10-25	2011-2015	with	_	_	
10-26	2016-2018	an	_	_	
10-27	2019-2028	equimolar	_	_	
10-28	2029-2035	amount	_	_	
10-29	2036-2038	of	_	_	
10-30	2039-2042	the	_	_	
10-31	2043-2048	other	_	_	
10-32	2049-2052	Fab	_	_	
10-33	2052-2053	'	_	_	
10-34	2053-2054	-	_	_	
10-35	2054-2057	TNB	_	_	
10-36	2058-2068	derivative	_	_	
10-37	2069-2071	to	_	_	
10-38	2072-2076	form	_	_	
10-39	2077-2080	the	_	_	
10-40	2081-2091	bispecific	_	_	
10-41	2092-2100	antibody	_	_	
10-42	2100-2101	.	_	_	

#Text=The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
11-1	2102-2105	The	_	_	
11-2	2106-2116	bispecific	_	_	
11-3	2117-2127	antibodies	_	_	
11-4	2128-2136	produced	_	_	
11-5	2137-2140	can	_	_	
11-6	2141-2143	be	_	_	
11-7	2144-2148	used	_	_	
11-8	2149-2151	as	_	_	
11-9	2152-2158	agents	_	_	
11-10	2159-2162	for	_	_	
11-11	2163-2166	the	_	_	
11-12	2167-2176	selective	_	_	
11-13	2177-2191	immobilization	_	_	
11-14	2192-2194	of	_	_	
11-15	2195-2202	enzymes	_	_	
11-16	2202-2203	.	_	_	
